Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393712 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
A Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06393712: Recruiting Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Alnylam Pharmaceuticals.
NCT06393712 is a Phase 2 study of Cerebral Amyloid Angiopathy that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06393712, a Phase 2 study of Cerebral Amyloid Angiopathy, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-APP
Study Locations (20)
California
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - Orange
- Clinical Trial Site - Palo Alto
- Clinical Trial Site - Sacramento
- Clinical Trial Site - San Francisco
Florida
- Clinical Trial Site - Gainesville
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Maitland
- Clinical Trial Site - Naples
Massachusetts
- Clinical Trial Site - Boston
- Clinical Trial Site - Plymouth
Colorado
- Clinical Trial Site - Aurora
Connecticut
- Clinical Trial Site - New Haven
Illinois
- Clinical Trial Site - Chicago
Kentucky
- Clinical Trial Site - Lexington
Louisiana
- Clinical Trial Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-05-17 |
| Est. Completion | 2029-12-14 |
| Phase | Phase 2 |
What NCT06393712 shows while recruiting
NCT06393712 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Cerebral Amyloid Angiopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06393712 names 20 study sites across 12 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06393712 about?
NCT06393712 is a clinical study titled "A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy". The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a...
What is the current status of trial NCT06393712?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-05-17. Estimated completion is 2029-12-14.
What conditions does trial NCT06393712 study?
This clinical trial studies the following conditions: Cerebral Amyloid Angiopathy.
What interventions are being tested in trial NCT06393712?
The interventions under investigation include: Placebo (DRUG), ALN-APP (DRUG).
Who is sponsoring clinical trial NCT06393712?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393712 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Amyloid Angiopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06393712's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI